Xcell Therapeutics risks KOSDAQ management-stock tag as market cap stays below KRW 20 billion
Bitget2026/10/12 08:22- Xcell Therapeutics faces potential KOSDAQ “management stock” designation if its common-share market cap stays below KRW 20 billion.
- The market cap had remained under the threshold for 25 consecutive trading days as of Oct. 12, 2026.
- Designation risk triggers if the sub-KRW 20 billion market cap persists for five more trading days from Oct. 13, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound: Wider trading range expected against US Dollar – UOB
Japan's Gradual "Capital Reflow": Japanese Bond Purchases Heat Up, No Major Retreat from Overseas Assets
Several leading Japanese asset management companies are expected to announce plans to increase their holdings of domestic bonds. The market is closely watching whether they will further reduce overseas assets to promote capital inflow back into Japan.
Korean stock earnings season starts next week; JPMorgan says storage stocks are entering a “season of expectation reset,” corrections present buying opportunities
JPMorgan believes that there is a divergence in perception among investors regarding the sustainability of AI spending and the underlying supply-demand fundamentals, and that excessive market sentiment has created an entry window for "duration trades"—betting on a "longer and higher" storage upcycle. The bank recommends overweight positions in industry leaders such as Samsung Electronics, SK Hynix, and Kioxia. The key verification point will be the earnings season starting from October 19.
British Pound holds gains as UK GDP and Industrial Production beat expectations
Crypto prices
More
